today to get expert help built just for you
In March 2026, topline results from the TRANSCEND-T2D-1 trials showed that participants with Type 2 diabetes achieved an average A1C reduction of up to 2.0% and lost nearly 17% of their body weight over 40 weeks
In this context, GLP-1RAs can inhibit the secretion of IL-2 and interferon (IFN)-, thereby regulating the immune microenvironment and preventing diabetes [144]
Were completing what pharma started
by Jennifer Lines, PharmD Candidate, PCCA Clinical Services Intern, and Catherine Henderson, PharmD, PCCA Clinical Compounding Pharmacist Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs
Gym locker rooms